Guide: IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both PD-1/PD-L1 and CD47/SIRP-alpha pathways.
Cinda Biopharmaceuticals has just announced that its potential lying phase I clinical study of anti-CD47/PD-L1 bispecific antibodies (research code: IBI322) has completed the first patient administration in China.
the study (CIBI322A101) is a phase Ia/Ib clinical study conducted in China to evaluate IBI322 treatment of subjects with advanced malignancies, the main purpose of which was to assess the safety, tolerance and antiactive tumors of IBI322 bispecific antibody therapy in subjects with advanced malignancies that failed standard treatment.
IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both The PD-1/PD-L1 and CD47/SIRP-alpha pathways.
preclinical studies show that IBI322 can effectively block the binding of SIRP-alpha and CD47, induce macrophages to perform a phagocytopharycal effect on tumor cells expressing CD47, the ability is comparable to anti-CD47 monoantiphoresis;
also due to the presence of PD-L1, IBI322 selectivebinding to tumor cells is more capable than anti-CD47 monogenic, thereby reducing the binding to CD47 on the surface of red blood cells, reducing the possibility of associated toxicity.
, IBI322 has better anti-tumor activity and greater safety. Professor Wang Jie, Director of Oncology Medicine at the Chinese Medical Hospital of
, said: "Although immunocheckpoint inhibitors have shown welcome results in the treatment of a wide range of tumors, they still face many new challenges.
With the increasing popularity of immunocheckpoint inhibitors in tumor therapy, a number of patients who are resistant to them have appeared clinically. At the same time
, the efficacy of immunocheckpoint inhibitors needs to be further improved.
, therefore, the development of the next generation of dual-specific tumor immunodrugs has important clinical significance.
CD47 is one of the most promising and potential targets in tumor immunotherapy, combined with the innovative technology of bispecific antibodies, the clinical results of IBI322 are very much expected. "Bispecific antibodies target effect cells directly against tumor cells, enhancing cytotoxicity and improving the selectivity and functional affinity of antibodies," said Dr. Hui Zhou, Vice President, Medical Science and Strategic Oncology, Cinda Biopharmaceutical Group,
preliminary results show that IBI322 has better in vivo efficacy, tumor concentration distribution, and higher safety than single-specific anti-CD47 antibodies.
bispecific antibodies can create lower drug costs for patients than two monoclonal antibody drugs combined with drug therapy.
, the development of anti-CD47/PD-L1 bispecific antibodies will provide patients with a new, comprehensive, effective and cost-effective treatment.
We hope iBI322 will benefit more patients.